कंपनी का अवलोकन
Avalon GloboCare Corp. operates as a real estate entity that owns and manages commercial properties across the United States while simultaneously distributing specialized healthcare technologies such as the KetoAir breathalyzer system and AI Nutritionist software. The company functions within the Real Estate sector, specifically under the industry classification of Real Estate Services, which suggests a business model focused on asset ownership rather than manufacturing or service provision. The enterprise possesses a market capitalization of $3.95M, generates annual revenue of $392,677, and employs a workforce of just 2 individuals. These valuation and revenue figures indicate that the company operates on a micro-cap scale, reflecting a very small market presence where financial metrics are highly sensitive to minor operational fluctuations. The combination of commercial real estate holdings and technology distribution creates a dual-revenue stream structure that is atypical for standard real estate firms, though the current scale remains limited by the low employee count and modest revenue base.
वित्तीय स्वास्थ्य
The company reported revenue of $392,677 over the trailing twelve-month period, yet it recorded a significant net income loss of $-17,356,400 and an EBITDA of $-7,496,916. The substantial disparity between the positive revenue figure and the massive negative net income reveals a highly inefficient cost structure where expenses far exceed earnings, potentially driven by one-time charges or structural overheads not covered by operating income. Free cash flow stands at $-1,903,116, which indicates a lack of financial flexibility and an inability to generate internal cash reserves to fund operations or investments without external capital injection. Margin analysis shows a Gross Margin of 100.0%, implying that the cost of goods sold is negligible or zero for its distribution activities, yet the Operating Margin of -1933.2% and Profit Margin of 0.0% demonstrate severe operational inefficiencies and overall unprofitability. Regarding liquidity, the company holds $109,091 in cash against $940,359 in total debt, resulting in a Debt to Equity ratio of 10.19, which signifies a heavily leveraged balance sheet with significant solvency risks. The Current Ratio is 0.11, indicating that current assets are less than 11% of current liabilities, which suggests a critical shortage of short-term liquidity to meet immediate obligations. Furthermore, the Return on Equity is -212.5% and the Return on Assets is -21.4%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently rather than generating returns.
मूल्यांकन आकलन
Trailing P/E and Forward P/E are both listed as N/A due to the negative earnings, which prevents traditional earnings-based valuation methods from being applied to the stock. The Price to Book ratio is -0.13, indicating that the market values the company at a fraction of its book value, or in this negative context, that the market capitalization is insufficient to cover the recorded book value of equity. The Price to Sales ratio is 10.07, while the EV/EBITDA stands at -4.31, suggesting that investors are pricing the asset based on revenue multiples despite the lack of earnings power, which often occurs in distressed or turnaround situations. The stock has a 52-Week High of $5.25 and a 52-Week Low of $0.42, providing a volatility range within which the trading price fluctuates based on market sentiment and technical factors. The Beta value is 0.10, which indicates that the stock price exhibits significantly lower volatility than the broader market, moving with only one-tenth the intensity of market swings. These valuation metrics collectively paint a picture of a high-risk, low-liquidity asset where traditional valuation signals are distorted by negative earnings and extreme leverage.
Growth & Income
Revenue Growth Year-over-Year and Earnings Growth Year-over-Year are both N/A, meaning historical growth trajectories cannot be calculated from the available data points to determine if earnings are expanding faster or slower than revenue. The company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which implies that the firm retains all negative earnings rather than distributing income to shareholders. Given the negative net income of $-17,356,400, the concept of a sustainable dividend payout is inapplicable since the company is unable to generate positive earnings to fund any distribution. The overall growth and income profile for Avalon GloboCare Corp. is characterized by a complete absence of growth data and income generation, presenting a challenging landscape for income-focused investors seeking capital appreciation or dividend yields.